Bevacizumab in combination with octreotide rescues a patient with liver cirrhosis, GAVE syndrome and refractory hemorrhage – a case report

Abstract

Gastric antral vascular ectasia (GAVE) syndrome is a rare but often challenging etiology of upper gastrointestinal bleeding (UGIB).

We report on a 60-year-old patient with liver cirrhosis, GAVE syndrome and recurrent and refractory GAVE-related UGIB. During a 5-month hospital stay, the patient required a total of 82 packed red blood cells (pRBCs) and 23 gastroscopies. All endoscopic approaches, including multiple argon plasma coagulation and band ligation sessions, remained unsuccessful. Antrectomy was waived because of the high perioperative mortality risk in Child-Pugh B liver cirrhosis. TIPS insertion also failed to control the bleeding. Only continuous intravenous octreotide infusion slowed the bleeding, but this forced the patient to be hospitalized. After 144 inpatient days, administration of subcutaneous octreotide allowed the patient to be discharged. However, the patient continued to require two pRBCs every 2–3 weeks. Based on recently published data, we treated the patient with bevacizumab (anti-VEGF antibody) off-label at a dose of 7.5 mg/kg body weight every three weeks in nine single doses over six months. Since the first administration, the patient has remained transfusion-free, has not required hospitalization, and leads an active life, working full-time. He remains on octreotide, which has been reduced but not yet discontinued. Additionally, no adverse events were observed.

Thus, in patients with liver cirrhosis and refractory GAVE-related hemorrhage, bevacizumab combined with subcutaneous octreotide should be considered as an effective and durable pharmacological treatment option.

Zusammenfassung

Das „Gastric antral vascular ectasia“ (GAVE-) Syndrom ist eine seltene, aber häufig herausfordernde Ursache der oberen gastrointestinalen Blutung (OGIB).

Wir berichten über einen 60-jährigen Patienten mit Leberzirrhose, GAVE-Syndrom und rezidivierenden, therapierefraktären GAVE-assoziierten OGIBs. Während eines 5-monatigen Krankenhausaufenthalts benötigte der Patient insgesamt 82 Erythrozytenkonzentrate (EKs) und 23 Gastroskopien. Alle endoskopischen Maßnahmen, einschließlich mehrfacher Argonplasmakoagulationen und Bandligaturen, blieben erfolglos. Auf eine Antrektomie wurde aufgrund des hohen perioperativen Mortalitätsrisikos bei Child-Pugh-B-Leberzirrhose verzichtet. Auch eine TIPS-Implantation konnte die Blutung nicht stillen. Eine kontinuierlich-intravenöse Octreotid-Infusion verlangsamte die Blutung, verlangte jedoch eine dauerhafte stationäre Behandlung. Nach 144 Tagen konnte der Patient durch die Umstellung auf eine subkutane Octreotid-Gabe schließlich entlassen werden. Der Patient blieb jedoch weiterhin transfusionsbedürftig. Auf Grundlage kürzlich veröffentlichter Daten behandelten wir den Patienten off-label mit Bevacizumab (Anti-VEGF-Antikörper) mit einer Dosis von 7,5 mg/kg Körpergewicht alle 3 Wochen in 9 Einzeldosen über 6 Monate. Seit der ersten Gabe wurden weder Transfusionen benötigt, noch musste der Patient stationär behandelt werden, sodass wieder eine aktive Teilnahme am Leben möglich ist. Die Octreotid-Dosis konnte zwar reduziert, jedoch noch nicht abgesetzt werden. Unter der Therapie mit Bevacizumab wurden keine unerwünschten Arzneimittelnebenwirkungen beobachtet.

Bei Patienten mit Leberzirrhose und refraktärer GAVE-assoziierter Blutung sollte Bevacizumab in Kombination mit subkutanem Octreotid als wirksame und dauerhafte pharmakologische Behandlungsoption in Betracht gezogen werden.

Schlüsselwörter

GAVE - Leberzirrhose - Octreotid - Bevacizumab - Kasuistik - Wassermelonenmagen

Keywords

GAVE - liver cirrhosis - octreotide - bevacizumab - case report - gastric antral vascular ectasia

Publication History

Received: 01 February 2022

Accepted: 06 October 2022

Article published online:
15 November 2022

• References

• 1 Dulai GS, Jensen DM, Kovacs TOG. et al. Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension. Endoscopy 2004; 36: 68-72 DOI: 10.1055/s-2004-814112.
• 2 Hsu WH, Wang YK, Hsieh MS. et al. Insights into the management of gastric antral vascular ectasia (watermelon stomach). Therap Adv Gastroenterol 2018; 11: 1756283X17747471 DOI: 10.1177/1756283X17747471.
• 3 Gostout CJ, Viggiano TR, Ahlquist DA. et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol 1992; 15: 256-263 DOI: 10.1097/00004836-199210000-00019.
• 4 Liberski SM, McGarrity TJ, Hartle RJ. et al. The watermelon stomach: Long-term outcome in patients treated with ND:YAG laser therapy. Gastrointestinal Endoscopy 1994; 40: 584-587 DOI: 10.1016/S0016-5107(94)70258-6.
• 5 Sargeant IR, Loizou LA, Rampton D. et al. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut 1993; 34: 470-475 DOI: 10.1136/gut.34.4.470.
• 6 Peng M, Guo X, Yi F. et al. Endoscopic treatment for gastric antral vascular ectasia. Ther Adv Chronic Dis 2021; 12 DOI: 10.1177/20406223211039696.
• 7 Hirsch BS, Ribeiro IB, Funari MP. et al. Endoscopic Band Ligation Versus Argon Plasma Coagulation in the Treatment of Gastric Antral Vascular Ectasia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Endosc 2021; 54: 669-677 DOI: 10.5946/ce.2021.063.
• 8 Nardone G, Rocco A, Balzano T. et al. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Alimentary pharmacology & therapeutics 1999; 13: 1429-1436 DOI: 10.1046/j.1365-2036.1999.00647.x.
• 9 Clarke DL, McKune A, Thomson SR. Octreotide lowers gastric mucosal blood flow in normal and portal hypertensive stomachs. Surg Endosc 2003; 17: 1570-1572 DOI: 10.1007/s00464-002-9274-z.
• 10 Peng M, Guo X, Yi F. et al. Pharmacotherapy for the Treatment of Gastric Antral Vascular Ectasia: A Narrative Review. Adv Ther 2021; 38: 5065-5077 DOI: 10.1007/s12325-021-01912-6.
• 11 Albitar HAH, Almodallal Y, Papadakis KA. et al. Intravenous Bevacizumab Reduces Transfusion Requirements and Endoscopic Interventions in Patients With Gastric Antral Vascular Ectasia and Small Bowel Angioectasia. Gastroenterology 2020; 158: 1162-1163.e4 DOI: 10.1053/j.gastro.2019.11.027.
• 12 Hurwitz H, Fehrenbacher L, Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine 2004; 350: 2335-2342 DOI: 10.1056/NEJMoa032691.
• 13 Sandler A, Gray R, Perry MC. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England journal of medicine 2006; 355: 2542-2550 DOI: 10.1056/NEJMoa061884.
• 14 Miller K, Wang M, Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England journal of medicine 2007; 357: 2666-2676 DOI: 10.1056/NEJMoa072113.
• 15 Robert NJ, Diéras V, Glaspy J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260 DOI: 10.1200/JCO.2010.28.0982.
• 16 Escudier B, Bellmunt J, Négrier S. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150 DOI: 10.1200/JCO.2009.26.7849.
• 17 Burger RA, Brady MF, Bookman MA. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England journal of medicine 2011; 365: 2473-2483 DOI: 10.1056/NEJMoa1104390.
• 18 Manning RJ. Estrogen/progesterone treatment of diffuse antral vascular ectasia. Am J Gastroenterol 1995; 90: 154-156
• 19 Hermans C, Goffin E, Horsmans Y. et al. Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen-progesterone therapy. Nephrol Dial Transplant 1996; 11: 871-874 DOI: 10.1093/oxfordjournals.ndt.a027418.
• 20 Patwardhan VR, Cardenas A. Review article: the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis. Alimentary pharmacology & therapeutics 2014; 40: 354-362 DOI: 10.1111/apt.12824.
• 21 Kamath PS, Lacerda M, Ahlquist DA. et al. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000; 118: 905-911 DOI: 10.1016/S0016-5085(00)70176-4.
• 22 Spahr L, Villeneuve JP, Dufresne MP. et al. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999; 44: 739-742 DOI: 10.1136/gut.44.5.739.
• 23 Novitsky Y. Watermelon Stomach Pathophysiology, Diagnosis, and Management. J Gastrointest Surg 2003; 7: 652-661 DOI: 10.1016/s1091-255x(02)00435-3.
• 24 van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. The Lancet 1990; 335: 953-955 DOI: 10.1016/0140-6736(90)91010-8.
• 25 Iyer VN, Apala DR, Pannu BS. et al. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding. Mayo Clin Proc 2018; 93: 155-166 DOI: 10.1016/j.mayocp.2017.11.013.
• 26 Santos S, Bernardes C, Borges V. et al. Gastric antral vascular ectasia (GAVE) and hereditary hemorrhagic telangiectasia (HHT): two different conditions, one treatment. Ann Hematol 2020; 99: 367-369 DOI: 10.1007/s00277-019-03845-1.